Mabwell to Unveil Clinical Findings of 9MW2821 and Toripalimab for Urothelial Carcinoma at ASCO 2025

Mabwell to Present Clinical Data at ASCO 2025

Mabwell, a biopharmaceutical company known for its innovative approaches, has announced that it will present significant clinical findings for its drug candidate 9MW2821 in combination with toripalimab. This key unveiling will take place at the upcoming American Society of Clinical Oncology (ASCO) annual meeting, scheduled from May 30 to June 3, 2025, in Chicago, USA. The event is highly regarded in the oncology field and attracts thousands of professionals, making it an ideal platform for such critical information exchange.

Focus of the Presentation

The centerpiece of Mabwell's presentation will be the Phase Ib/II clinical study results focusing on patients with locally advanced or metastatic urothelial carcinoma (la/mUC). This condition is known for its complexity and challenging treatment landscape, hence this research could hold significant implications for treatment outcomes. The oral presentation titled "9MW2821, a novel Nectin-4 antibody-drug conjugate (ADC), combined with toripalimab in treatment-naive patients with locally advanced or metastatic urothelial carcinoma" will be showcased by Prof. Sheng Xinan, a chief physician at the Department of Urologic Oncology at Beijing Cancer Hospital.

The abstract number for this presentation is 4519, and it falls under the Rapid Oral Abstract Session dedicated to Genitourinary Cancer, specifically focusing on kidney and bladder cancers. The scheduled session time is from 1:15 PM to 2:45 PM CDT on May 31, 2025.

Poster Presentations

In addition to the oral presentation, Mabwell will also provide insights through several poster presentations, further cementing its commitment to sharing critical innovations in cancer treatment. The posters will include:
1. Phase 1/2 Study of 7MW3711 - A novel B7-H3 antibody-drug conjugate (ADC) with a topoisomerase I inhibitor targeting advanced solid tumors.
- Abstract Number: 3035
- Session Type: Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology
- Date and Time: June 2, 2025, from 1:30 PM to 4:30 PM CDT.

2. Phase 1/2 Study of 7MW3711 in Lung Cancer.
- Abstract Number: 3036
- Session Type: Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology
- Date and Time: Same as above.

3. First-in-Human Clinical Study of 9MW2921 - A novel TROP-2 antibody-drug conjugate.
- Abstract Number: 3029
- Session Type: Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology
- Date and Time: Also on June 2, 2025.

About Mabwell

Mabwell (688062.SH) is an innovative biopharmaceutical company recognized for its comprehensive approach throughout the entire pharmaceutical development spectrum. Established in 2017, Mabwell is dedicated to providing improved and accessible therapies on a global scale. Currently, it has an impressive pipeline featuring 16 products at varying stages of development, including 12 novel drug candidates and 4 biosimilars. The company has three products already approved for market, with further candidates undergoing pivotal trials.

The company operates a robust in-house manufacturing facility in Taizhou and maintains adherence to international Good Manufacturing Practice (GMP) standards, ensuring quality compliance from regulatory bodies like the NMPA, FDA, and EMA. As part of its commitment to advancing healthcare through innovative research and development, Mabwell’s mission is to explore life and benefit health, with a vision of translating innovative ideas into tangible medical solutions.

With its active participation in critical events like ASCO, Mabwell continues to position itself as a leader in biopharmaceutical innovation, keenly focused on addressing unmet medical needs with groundbreaking solutions.